Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 12, 2026, 8:23 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 1,706 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Dementia Praecox Clear all
Completed Phase 1 Interventional

A Safety and PK Study of Injectable Risperidone-SABER and the DosePro Delivery System in Patients With Schizophrenia

NCT01592110
View directory record Official record
Conditions
Schizophrenia
Interventions
Risperidone-SABER, ZX003:risperidone-SABER and the DosePro System
Drug · Other
Lead sponsor
Zogenix, Inc.
Industry
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
1
States / cities
Glendale, California
Source: ClinicalTrials.gov public record
Updated Nov 9, 2022 · Synced Sep 12, 2026, 8:23 AM EDT
Completed Phase 1 Interventional

A Phase 1 Safety Study in Adults With Schizophrenia

NCT02804568
View directory record Official record
Conditions
Schizophrenia
Interventions
ALKS 3831
Drug
Lead sponsor
Alkermes, Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016
U.S. locations
3
States / cities
Little Rock, Arkansas • Clementon, New Jersey • Dayton, Ohio
Source: ClinicalTrials.gov public record
Updated Sep 21, 2016 · Synced Sep 12, 2026, 8:23 AM EDT
Completed Early Phase 1 Interventional

Pharmacologic and Clinical Testing of a D1 Agonist for Cognitive Enhancement in Neuropsychiatric Disorders

NCT01519557
View directory record Official record
Conditions
Schizophrenia, Schizoaffective Disorder
Interventions
DAR-100A, Placebo
Drug
Lead sponsor
New York State Psychiatric Institute
Other
Eligibility
18 Years to 55 Years
Enrollment
68 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Mar 3, 2015 · Synced Sep 12, 2026, 8:23 AM EDT
Completed Phase 2 Interventional Results available

Study of the Safety, Tolerability, and Pharmacokinetics of Once Weekly Zicronapine in Patients With Schizophrenia

NCT01377233
View directory record Official record
Conditions
Schizophrenia
Interventions
Zicronapine open-label lead-in 10 mg daily, Zicronapine 10 mg daily, Zicronapine 20 mg once weekly, Zicronapine 30 mg once weekly, Zicronapine 45 mg once weekly
Drug
Lead sponsor
H. Lundbeck A/S
Industry
Eligibility
18 Years to 65 Years
Enrollment
46 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2011
U.S. locations
4
States / cities
Garden Grove, California • National City, California • San Diego, California + 1 more
Source: ClinicalTrials.gov public record
Updated Mar 21, 2016 · Synced Sep 12, 2026, 8:23 AM EDT
Completed Phase 3 Interventional Results available

Study to Assess Safety and Effectiveness of Slowly Increasing Dose and Food Effect of KarXT in Participants With Schizophrenia

NCT06572449
View directory record Official record
Conditions
Schizophrenia
Interventions
KarXT
Drug
Lead sponsor
Karuna Therapeutics, Inc., a Bristol Myers Squibb company
Industry
Eligibility
18 Years to 65 Years
Enrollment
173 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
6
States / cities
Los Alamitos, California • Riverside, California • Hollywood, Florida + 3 more
Source: ClinicalTrials.gov public record
Updated Jun 21, 2026 · Synced Sep 12, 2026, 8:23 AM EDT
Completed Phase 1 Interventional

Evaluate the PK of LY03010 Process 1 and Process 2 Drug Product vs INVEGA SUSTENNA After Intramuscular Injection in Schizophrenia Patients

NCT04572685
View directory record Official record
Conditions
Schizophrenia Patients
Interventions
Paliperidone Palmitate
Drug
Lead sponsor
Luye Pharma Group Ltd.
Industry
Eligibility
18 Years to 65 Years
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020
U.S. locations
1
States / cities
Berlin, New Jersey
Source: ClinicalTrials.gov public record
Updated Nov 8, 2020 · Synced Sep 12, 2026, 8:23 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

OnTrack>An Online Role-Playing Game for Young People With First Episode Psychosis

NCT03390491
View directory record Official record
Conditions
Psychosis, Schizoaffective Disorder, Schizophrenia
Interventions
OnTrack>TheGame (OTG), Recovery Videos (RV)
Behavioral
Lead sponsor
Center for Social Innovation, Massachusetts
Other
Eligibility
16 Years to 30 Years
Enrollment
160 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2021
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Nov 25, 2021 · Synced Sep 12, 2026, 8:23 AM EDT
Completed Phase 3 Interventional Results available

Lurasidone HCl A Phase 3 Study of Patients With Acute Schizophrenia

NCT00615433
View directory record Official record
Conditions
Schizophrenia
Interventions
Lurasidone, Olanzapine, Placebo comparator, Lurasidone 40 mg tablets
Drug
Lead sponsor
Sumitomo Pharma America, Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
478 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
25
States / cities
Little Rock, Arkansas • Cerritos, California • Oceanside, California + 20 more
Source: ClinicalTrials.gov public record
Updated Jun 11, 2015 · Synced Sep 12, 2026, 8:23 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Neuroplasticity in TBI and Schizophrenia

NCT03995368
View directory record Official record
Conditions
Schizophrenia, Traumatic Brain Injury
Interventions
Electroencephalography
Other
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
25 Years to 55 Years
Enrollment
93 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2023
U.S. locations
1
States / cities
West Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Sep 18, 2024 · Synced Sep 12, 2026, 8:23 AM EDT
Completed Not applicable Interventional

A Prospective Cohort Study to Assess Clinical Effectiveness of an Investigational Digital Therapeutic (CT-155) in Patients With Experiential Negative Symptoms of Schizophrenia

NCT06791122
View directory record Official record
Conditions
Schizophrenia
Interventions
Digital therapeutic (CT-155)
Device
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
18 Years and older
Enrollment
262 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
31
States / cities
Imperial, California • La Jolla, California • Oceanside, California + 25 more
Source: ClinicalTrials.gov public record
Updated Sep 8, 2026 · Synced Sep 12, 2026, 8:23 AM EDT
Completed Not applicable Interventional

Understanding How Cognitive Remediation Works

NCT01683539
View directory record Official record
Conditions
Schizophrenia, Schizoaffective Disorder, Chronic Mental Disorder, Major Depression, Bipolar Disorder
Interventions
The Thinking Skills for Work Program, The Cognitive Skills for Work Program
Behavioral
Lead sponsor
Boston University Charles River Campus
Other
Eligibility
18 Years and older
Enrollment
203 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2019
U.S. locations
2
States / cities
Chicago, Illinois • Manchester, New Hampshire
Source: ClinicalTrials.gov public record
Updated Mar 12, 2019 · Synced Sep 12, 2026, 8:23 AM EDT
Completed Phase 3 Interventional Results available

A Twelve Week, Open Label Extension Study in Patients With Schizophrenia

NCT01566162
View directory record Official record
Conditions
Schizophrenia
Interventions
Lurasidone
Drug
Lead sponsor
Sumitomo Pharma America, Inc.
Industry
Eligibility
18 Years and older
Enrollment
191 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
38
States / cities
Little Rock, Arkansas • Cerritos, California • Downey, California + 31 more
Source: ClinicalTrials.gov public record
Updated Apr 8, 2019 · Synced Sep 12, 2026, 8:23 AM EDT
Completed Phase 2 Interventional Results available

A Study of Tolerability and Efficacy of Cannabidiol on Motor Symptoms in Parkinson's Disease

NCT03582137
View directory record Official record
Conditions
Parkinson Disease
Interventions
Cannabidiol, Placebo
Drug · Other
Lead sponsor
University of Colorado, Denver
Other
Eligibility
40 Years to 85 Years
Enrollment
74 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Jul 22, 2024 · Synced Sep 12, 2026, 8:23 AM EDT
Withdrawn Not applicable Interventional

Repetitive Transcranial Magnetic Stimulation (rTMS) Self-Referential Processing (rTMS-SRP)

NCT04068857
View directory record Official record
Conditions
Schizophrenia, Schizo Affective Disorder
Interventions
rTMS
Device
Lead sponsor
Indiana University
Other
Eligibility
18 Years to 45 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
2
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Nov 20, 2019 · Synced Sep 12, 2026, 8:23 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Enhancing Cognitive Training Through Exercise After a First Schizophrenia Episode

NCT02267070
View directory record Official record
Conditions
Schizophrenia, Schizophreniform Disorder, Schizoaffective Disorder
Interventions
Case management and supportive psychotherapy, Family psychoeducation, Cognitive training, Aerobic exercise
Behavioral
Lead sponsor
University of California, Los Angeles
Other
Eligibility
18 Years to 45 Years
Enrollment
48 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2017
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Dec 6, 2017 · Synced Sep 12, 2026, 8:23 AM EDT
Active, not recruiting Not applicable Interventional

Psychosis TMS Study

NCT05857137
View directory record Official record
Conditions
Psychosis
Interventions
Active TMS, Placebo TMS
Device
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years to 35 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
1
States / cities
Charlestown, Massachusetts
Source: ClinicalTrials.gov public record
Updated Sep 10, 2026 · Synced Sep 12, 2026, 8:23 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Nicotinic Modulation of Schizophrenia-like Information Processing Deficits in Healthy Subjects

NCT00690170
View directory record Official record
Conditions
Healthy Subjects
Interventions
Ketamine, Nicotine, Placebo, Ketamine and Nicotine
Drug
Lead sponsor
Yale University
Other
Eligibility
18 Years to 50 Years
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2002 – 2009
U.S. locations
1
States / cities
West Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated May 8, 2012 · Synced Sep 12, 2026, 8:23 AM EDT
Completed Phase 4 Interventional Results available

Study to Measure the Safety of Paliperidone ER (Extended-release) in Patients With Liver Disease

NCT00535145
View directory record Official record
Conditions
Schizophrenia, Schizoaffective Disorder, Psychotic Disorders
Interventions
Treatment as usual (TAU), Paliperidone ER
Drug
Lead sponsor
Ortho-McNeil Janssen Scientific Affairs, LLC
Industry
Eligibility
18 Years and older
Enrollment
121 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
21
States / cities
Cerritos, California • Chino, California • Garden Grove, California + 18 more
Source: ClinicalTrials.gov public record
Updated Jul 24, 2014 · Synced Sep 12, 2026, 8:23 AM EDT
Completed Phase 2Phase 3 Interventional

Effect of Ziprasidone on Glucose & Plasma Lipids in Diabetes (II) and Schizophrenia or Schizoaffective Disorder

NCT00395031
View directory record Official record
Conditions
Schizophrenia, Schizoaffective Disorder
Interventions
Ziprasidone
Drug
Lead sponsor
Manhattan Psychiatric Center
Other
Eligibility
18 Years to 65 Years
Enrollment
57 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2010
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jul 28, 2011 · Synced Sep 12, 2026, 8:23 AM EDT
Completed Phase 2Phase 3 Interventional

Study of Alternate Formulation of Aripiprazole in Agitated Patients With Schizophrenic Disorders

NCT00036127
View directory record Official record
Conditions
Schizophrenia
Interventions
aripiprazole
Drug
Lead sponsor
Otsuka Pharmaceutical Development & Commercialization, Inc.
Industry
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2003
U.S. locations
16
States / cities
Anaheim, California • Cerritos, California • Chula Vista, California + 13 more
Source: ClinicalTrials.gov public record
Updated Nov 10, 2013 · Synced Sep 12, 2026, 8:23 AM EDT
Completed Phase 1 Interventional

An Open-Label Trial to Assess the Comparative Bioavailability of TV-44749 to Oral Olanzapine in Participants With Schizophrenia

NCT06315283
View directory record Official record
Conditions
Schizophrenia
Interventions
TV-44749, Oral olanzapine
Drug
Lead sponsor
Teva Branded Pharmaceutical Products R&D LLC
Industry
Eligibility
18 Years to 64 Years
Enrollment
153 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
6
States / cities
Los Alamitos, California • Torrance, California • Hollywood, Florida + 3 more
Source: ClinicalTrials.gov public record
Updated Jan 13, 2026 · Synced Sep 12, 2026, 8:23 AM EDT
Completed Not applicable Interventional Results available

Improving Hallucinations by Targeting the rSTS With tES

NCT05165654
View directory record Official record
Conditions
Hallucinations, Auditory, Psychosis
Interventions
Transcranial Electrical Stimulation
Device
Lead sponsor
Beth Israel Deaconess Medical Center
Other
Eligibility
18 Years to 50 Years
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Sep 16, 2025 · Synced Sep 12, 2026, 8:23 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Brain Stimulation, Clinical Symptoms and Cognition

NCT05053451
View directory record Official record
Conditions
Schizophrenia
Interventions
Transcranial Direct Current Stimulation
Device
Lead sponsor
University of California, Davis
Other
Eligibility
18 Years to 65 Years
Enrollment
5 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2024
U.S. locations
1
States / cities
Sacramento, California
Source: ClinicalTrials.gov public record
Updated May 16, 2024 · Synced Sep 12, 2026, 8:23 AM EDT
Completed Phase 1 Interventional

A Study of the Safety, Tolerability and Pharmacokientics of RO5545965 in Patients With Schizophrenia on Risperidone

NCT02019329
View directory record Official record
Conditions
Schizophrenia
Interventions
Placebo, RO5545965, risperidone
Other · Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years to 60 Years
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014
U.S. locations
1
States / cities
Glendale, California
Source: ClinicalTrials.gov public record
Updated Nov 1, 2016 · Synced Sep 12, 2026, 8:23 AM EDT